Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis

SIMPLE SUMMARY: Although cisplatin is very effective as a treatment strategy in triple-negative breast cancer (TNBC), it has unwarranted outcomes owing to recurrence, chemoresistance and neurotoxicity. In the current studies we determined a novel therapeutic option that enhances the efficacy of cisp...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez, Emma, Pei, Guangsheng, Kim, Sang T., German, Alexis, Robinson, Prema
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345440/
https://www.ncbi.nlm.nih.gov/pubmed/34359773
http://dx.doi.org/10.3390/cancers13153871

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345440/
https://www.ncbi.nlm.nih.gov/pubmed/34359773
http://dx.doi.org/10.3390/cancers13153871

Ejemplares similares